Anti-BRG1/SMARCA4 Antibody, clone 20C3.2 ZooMAb^® Mouse Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 20C3.2 is a ZooMAb^® mouse recombinant monoclonal antibody that specifically detects transcription activator BRG1 (SMARCA4).

GST-tagged recombinant protein corresponding to the human BRG1/ SMARCA4.

Quality Control Testing

Evaluated by Western Blotting in K562 cell lysate.

Western Blotting Analysis (WB): A 1:10,000 dilution of this antibody detected BRG1/SMARCA4 in K562 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected BRG1/SMARCA4 in HeLa cell nuclear extract and 1:1,000 dilution detected BRG1/SMARCA4 in C6 cell lysate.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected BRG1/SMARCA4 in Human prostate and Human kidney tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected BRG1/SMARCA4 in HeLa cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Transcription activator BRG1 (UniProt: P51532; also known as ATP-dependent helicase,  SMARCA4, BRG1-associated factor 190A, BAF190A, Mitotic growth and transcription activator, Protein BRG-1, Protein brahma homolog 1, SNF2-beta, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4) is encoded by the SMARCA4 (also known as BAF190A, BRG1, SNF2B,  SNF2L4) gene (Gene ID: 6597) in human. BRG1 is a component of the multiprotein chromatin-remodeling complexes SWI/SNF: SWI/SNF-A (BAF), SWI/SNF-B (PBAF) and related complexes. It is involved in transcriptional activation and repression of select genes by chromatin remodeling. The SWI/SNF complexes contain 10-12 interchangeable subunits, with either BRG1/SMARCA4 or BRM/SMARCA2 as the ATPase subunit. These complexes drive conformational changes of nucleosomes in an ATP-dependent manner and play important roles in cell-cycle progression, DNA repair, and development. BRG1 is shown to maintain polycomb-mediated repression of non-mesodermal developmental regulators. Studies have shown that BRG1 knockout LEADS^™ to disruption of murine ESC cardiomyocyte differentiation and dysregulation of lineage-specific gene expression during mesoderm induction. BRG1 has been implicated in growth control through its interaction with the tumor suppressor pRb and may consequently serve as a negative regulator of proliferation. Mutations in SMARCA4 gene that results in BRG1 inactivation are observed in several cancer cells. Some mutations are also known to cause rhabdoid tumor predisposition syndrome 2 that predisposes subject to renal or extrarenal malignant rhabdoid tumors. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, Affinity^™, reproducibility, and stability over conventional monoclonals. (Ref.: Wong, AK., et al. (2000). Cancer Res. 60(21); 6171-6177; Khavari, PA., et a. (1993). Nature. 366(6451); 170-174).

Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Affinity is a trademark of Mine Safety Appliances Co.

LEADS is a trademark of Compugen

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.